• Integrating Stromal Subtypes into Gastric Cancer Assembloid

  2026-05-06

  This study presents a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, closely replicating the tumor microenvironment. The model enables improved investigation of tumor-stroma interactions and drug resistance, supporting more physiologically relevant preclinical drug testing and personalized therapy design.

• CRL4DCAF13 E3 Ligase Controls MeCP2 to Regulate Oocyte Epige

  2026-05-06

  This study uncovers how the CRL4DCAF13 E3 ubiquitin ligase complex targets MeCP2 for degradation in growing oocytes, preventing DNA hypermethylation and transcriptional dysregulation. These findings establish a critical epigenetic quality control mechanism relevant to both oocyte maturation and ovarian aging.

• (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)...: Mechanistic

  2026-05-05

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) is redefining research on the Nrf2 pathway and osteoclastogenesis. Explore advanced applications and technical insights that move beyond previous reviews, revealing how this APExBIO compound enables next-generation biochemical research.

• TCEP Hydrochloride: Redefining Reductive Workflows in Transl

  2026-05-05

  This thought-leadership article explores the mechanistic precision and strategic value of Tris(2-carboxyethyl) phosphine hydrochloride (TCEP hydrochloride) in advancing capture-and-release workflows, high-sensitivity protein assays, and translational biomarker research. Drawing on recent innovations in lateral flow assay enhancement and robust experimental validation, we position TCEP hydrochloride from APExBIO as a central tool for translational researchers seeking next-generation workflow reliability, clinical relevance, and workflow scalability.

• Optimizing Cell Assays with Wnt Agonist 1 (SKU B6059): Relia

  2026-05-04

  This article delivers practical, scenario-driven insights for biomedical labs utilizing Wnt agonist 1 (SKU B6059) in cell viability, proliferation, and differentiation assays. By addressing common workflow challenges and providing evidence-based recommendations, it highlights how APExBIO’s high-purity BML-284 ensures reproducibility and robust Wnt signaling pathway activation for demanding research applications.

• Docetaxel in Cancer Chemotherapy Research: Applied Workflows

  2026-05-04

  Docetaxel (Taxotere) stands out as a microtubule stabilization agent with proven potency in breast, ovarian, and gastric cancer models. This article breaks down data-driven workflows, troubleshooting strategies, and recent innovations—empowering cancer researchers to maximize reproducibility and interpretability in apoptosis and resistance studies.

• Entecavir for Chronic Hepatitis B with Decompensated Cirrhos

  2026-05-03

  This review by Keating provides a comprehensive synthesis of clinical and pharmacological evidence on Entecavir (BMS200475) for treating chronic hepatitis B virus (HBV) in patients with decompensated liver disease. The analysis highlights Entecavir’s robust viral suppression, high barrier to resistance, and relevance for lamivudine-resistant cases, with nuanced discussion of safety and dosing in vulnerable populations.

• CD28-ARS2-PKM Axis Drives CD8+ T Cell Metabolic Flexibility

  2026-05-02

  This study uncovers how CD28-driven ARS2 upregulation orchestrates alternative splicing of the PKM gene, enabling CD8+ T cells to adapt their glucose metabolism for optimal antitumor responses. The findings reveal a novel posttranscriptional regulatory mechanism in immunometabolism, with implications for designing metabolic interventions in cancer immunotherapy.

• Viperin Inhibits Coronavirus RTC Assembly via nsp8 Disruptio

  2026-05-01

  This article reviews Zhou et al.'s discovery that viperin inhibits coronavirus replication by binding to the non-structural protein 8 (nsp8), thereby disrupting the replication-transcription complex (RTC) and reducing RNA synthesis. The findings elucidate a conserved, broad-spectrum antiviral mechanism and clarify the distinct roles of viperin's enzymatic and protein-protein interaction activities.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Protein

  2026-05-01

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO ensures uncompromised protein integrity during extraction and phosphorylation-sensitive assays. Its EDTA-free, broad-spectrum formulation protects target proteins without interfering with divalent cation-dependent processes, enabling reproducible, high-fidelity results for Western blotting, co-immunoprecipitation, and kinase analyses.

• FITC-Concanavalin A (ConA) Conjugate: Technical Use Guide

  2026-04-30

  FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of α-D-glucose and α-D-mannose residues on cell surfaces, supporting precise workflows in immunofluorescence, flow cytometry, and glycobiology. This reagent is not suitable for non-carbohydrate-binding applications or for use beyond its defined stability and storage conditions.

• DMH-1 (B3686): Potent ALK2 Inhibitor for BMP Pathway Researc

  2026-04-30

  DMH-1 is a highly selective ALK2 inhibitor for precise BMP pathway modulation. It enables reproducible suppression of Smad1/5/8 phosphorylation and Id gene expression in cancer and organoid models. This article details DMH-1’s validated mechanism, application scope, and protocol guidance for non-small cell lung cancer and advanced organoid research.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-04-29

  This study introduces a gastric cancer assembloid model integrating matched tumor organoids and stromal cell subpopulations derived from the same patient. The innovation enables more physiologically relevant drug testing and mechanistic studies of tumor-stroma crosstalk, providing a platform for personalized therapy optimization.

• SMYD2 Inhibition Reduces RCC Progression and Drug Resistance

  2026-04-29

  This study demonstrates that targeting the histone methyltransferase SMYD2 suppresses tumor progression and attenuates multidrug resistance in clear cell renal cell carcinoma (ccRCC). Through mechanistic dissection involving the SMYD2/miR-125b/P-glycoprotein axis, the research offers new insights into overcoming chemoresistance in RCC and suggests novel biomarkers for prognosis and therapy.

• SARS-CoV-2 N Protein Disrupts GADD34-IRF3 Immune Axis via At

  2026-04-28

  This study reveals a mechanism by which the SARS-CoV-2 nucleocapsid protein impairs host innate immunity: by sequestering GADD34 mRNA into atypical stress granule-like foci, it disrupts IRF3 nuclear translocation and interferon signaling. These findings highlight novel viral strategies for immune evasion and suggest new molecular targets for studying host-virus interactions.

16132 records 1/1076 page Next 12345 下5页 Last page